Author

J. Femel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1

Frequent Co-Authors

A. W. Lund· 3 shared S. A. Leachman· 2 shared A. Rogiers· 1 shared C. Hill· 1 shared D. Lambrechts· 1 shared D. Murugan· 1 shared D. Pedri· 1 shared E. Leucci· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. W. Lund

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

T cell Egress via Lymphatic Vessels Limits the Intratumoral T cell Repertoire in Melanoma

M. M. Steele, I. D. Dryg, D. Murugan, J. Femel, H. du Bois, C. Hill, S. A. Leachman, Y. H. Chang, L. M. Coussens, A. W. Lund

The paper shows that T cell egress via lymphatic vessels limits intratumoral T cell diversity, and that CXCR4 inhibition enhances T cell retention and improves immunotherapy response.

bioRxiv · May 30, 2022 · PreprintImmunology

Quantitative multiplex immunohistochemistry reveals inter- and intra-patient lymphovascular and immune heterogeneity in primary cutaneous melanoma

J. Femel, J. L. Booth, T. G. Asnaashari, S. A. Leachman, T. Tsujikawa, K. White, Y. H. W. Chang, A. W. Lund

This paper uses quantitative multiplex immunohistochemistry to analyze lymphovascular and immune heterogeneity in primary cutaneous melanoma, finding that vessel subtypes correlate with immune infiltration and metastatic risk.

bioRxiv · Oct 8, 2021Cancer Biology

A neural crest stem cell-like state drives nongenetic resistance to targeted therapy in melanoma

O. Marin-Bejar, A. Rogiers, M. Dewaele, J. Femel, P. Karras, J. Pozniak, G. Bervoets, N. Van Raemdonck, D. Pedri, T. Swings, J. Demeulemeester, S. Vander Borght, F. Bosisio, J. J. van den Oord, I. Vanden Bempt, , J.-C. Marine

This study identifies a neural crest stem cell-like state in melanoma minimal residual disease that drives nongenetic resistance to MAPK-targeted therapy and shows that targeting FAK/SRC signaling can delay relapse.

bioRxiv · Dec 15, 2020 · PreprintCancer Biology